Jazz Pharmaceuticals Posts Record Revenue, Eyes Zanidatamab Launch in 2026
Event summary
- Jazz Pharmaceuticals reported $4.3 billion in total revenue for 2025, a 5% year-over-year increase.
- Xywav and Epidiolex generated $1.7 billion and $1.1 billion in revenue, respectively, with double-digit growth.
- Modeyso, launched in August 2025, achieved $48 million in sales.
- Company expects to submit sBLA for zanidatamab in 1Q26, with potential launch in 1L HER2+ GEA in 2H26.
- 2026 revenue guidance set at $4.25 to $4.50 billion.
The big picture
Jazz Pharmaceuticals continues to strengthen its position in rare diseases and oncology with record revenue and strategic pipeline advancements. The company's focus on zanidatamab and sustained growth in its sleep and epilepsy franchises underscores its commitment to innovation and long-term value creation. The biopharmaceutical sector is increasingly competitive, making Jazz's ability to execute on regulatory and commercial milestones crucial for maintaining its market leadership.
What we're watching
- Regulatory Milestones
- The completion of the sBLA submission for zanidatamab in 1Q26 and its potential launch in 2H26 will be critical for Jazz's oncology growth strategy.
- Market Positioning
- Whether Jazz can sustain double-digit growth across its epilepsy and oncology franchises amid competitive pressures.
- Execution Risk
- The pace at which Modeyso and Zepzelca can achieve commercial success post-launch will impact Jazz's revenue diversification.
Related topics